Greece Cancer Test

THE GREECE TEST: BRIEF EXPLANATION AND FACTS!

 Why is the CHEMO-SENSITIVITY/CHEMO-RESISTIVITY {CS/CR} not recognized more today?

 A statement made by Larry M.  Weisenthal, M.D., Ph.D. on 5/25/2003 answers this question.  He stated: "in my experience, I have never found a single NCI {NATIONAL CANCER INSTITUTE}, NCI-CCC (NCI-designated Comprehensive Cancer Centers), or an American university-based oncologist or researcher who has either the facts or command of concepts to discuss the issue of CS/CR intelligently." EMPHASIS ADDED

Basically this creates two choices:

•1)      Proof beyond reasonable doubt (argues against the use of CS/CR).

•2)      Weight of currently available evidence  (argues in favor of the use of the CS/CR).

"Stupid is as stupid does."  Forrest Gump

 WHAT MAKES THE GREECE TEST SUPERIOR?

 1. Use of state-of-the-art molecular biology techniques (micro-array, PCR, RT-PCR, southern and less northern blot, etc.). Previous technology used clonogenic, ATP-TCA, MTT, and SRB assays which are accurate, more restrictive in their results and less efficient.

 2. Investigate genes that are necessary for the growth and survival of the tumor.

 3. Investigate the mechanisms by which the cancer cells resists chemotherapeutic drugs (MDR1 protein,  LRP protein, glutathione transferase, gene amplification, etc.).

 4. Test for mechanisms of neovascularization and infiltration of the tumor, which is necessary for tumor metastasis.

 5. Tests for about 50+ nutrients which can cause  apoptosis of the cancer cells, act as anti-angiogenesis factors, anti-tumor growth factors, help decrease expression of MDR1, help regulate P27 and P53 pathways, and stimulate tremendous immune responses etc.  Also testing all the chemo drugs not just those approved by the FDA for your type of cancer, thereby creating a truly individual treatment program.

6. Specifically test by micro-array technique the heat shock proteins (HSP) that shows if the cancer cells are sensitive to hyperthermia treatments and/or radiotherapy.

7. The entire test from time of shipping to the point of receiving results is 7 to 10 working days.  Previous techniques need 30-40+ days to receive results.

8. Both scientifically and clinically there is considerably less false positive and negative results than seen  in previous techniques.

9. Previous techniques used cell cultures and test cell lines from tissue samples only.  The cell line is only one subclone from the total metastatic cancer cell population.  Therefore, the analysis provides information only for this subclone. In micro-array the analysis involves testing of all the metastatic subclones from the tumor.

10. Previous techniques could only use tissue samples which are not always available, especially in advanced stages of disease.  Micro-array can be made by isolation of circulating cancer cells found in peripheral blood. This allows clinicians to perform this test by blood draw in the office not just with  biopsy.

 HOW CAN THIS TEST BENEFIT BOTH THE PATIENT AND HEALTH CARE PROVIDER?

1. Helps the health care provider(s) determine a more targeted and exact approach for a support customized for each individual cancer patient.
2. Clinically we see the patient respond much faster and with a significant decrease in all forms of chemo side effects.
3. Out of the nutritional products tested we can find those nutrients that actually have an apoptotic effect on the cancer cells and those that inhibit their growth, metastasis or angiogenesis.  This again is an individual customized program for each individual cancer patient.
4. Clinically we find this test useful as a initial screening device (not to replace biopsy) if a patient is concerned about, do they actually have cancer.
5. We will also use this test to help determine the progress or lack thereof during their treatment  program.  We will usually do this at three month intervals, just the basic test only.
6. This test is also extremely beneficial for determining the likelihood of micro-metastasis occurring whether the patient is responding to treatment or not. {tumor stim cell markers}
7. The test is also used to better help us determine when the patient is in actual remission.
8. We will re-test patients that have been shown to be in remission about every six months to a year to see if there is a relapse.

 M.R.D. {MINIMAL RESIDUAL DISEASE} *THIS IS A HUGE PROBLEM AND DANGEROUS

 LIMITS OF VARIOUS DIAGNOSTIC TECHNIQUES:

 10¹² CELLS: ABOVE THIS LIMIT THE COMPATIBLE DIAGNOSTICS CAN DETECT A TUMOR MASS. [1 trillion]    MOST ALL DIAGNOSTIC TECHNIQUES CAN FIND TUMORS THIS BIG, EVEN PALPATION.         

 10⁹ CELLS: BELOW THIS LIMIT THE CLINICAL DIAGNOSTICS CANNOT DETECT THE EXISTENCE OF A TUMOR. [1 billion]   MAYBE ONLY THE NEWEST CT SCANNERS CAN LOCATE TUMORS.

 10¹ CELLS: R.G.C.C. CAN DETECT CELLS AT THIS LEVEL.  EXTREMELY SENSITIVE.

PCR=polymerase chain reaction; RT-PCR=reverse transcription polymerase chain reaction; ATP-TCA= ATP tumor chemosensitivity assay; MTT= molecular targeted therapies (act like modifiers); SRB=sulforhodamine-B ( any fluorescence dye primarily used as a polar tracer).